NCT00005853View on ClinicalTrials.gov

Biological Therapy in Treating Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 1999

Primary Completion Date

August 31, 2005

Study Completion Date

August 31, 2005

Conditions
LeukemiaMyelodysplastic Syndromes
Interventions
BIOLOGICAL

anti-thymocyte globulin

BIOLOGICAL

etanercept

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00005853 - Biological Therapy in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter